OVERSEA CHINESE BANKING Corp Ltd Has $29.03 Million Position in Illumina, Inc. $ILMN

OVERSEA CHINESE BANKING Corp Ltd reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 304,247 shares of the life sciences company’s stock after selling 6,233 shares during the period. Illumina comprises about 0.8% of OVERSEA CHINESE BANKING Corp Ltd’s investment portfolio, making the stock its 29th largest holding. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Illumina were worth $29,028,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ILMN. Corvex Management LP boosted its position in shares of Illumina by 125.2% during the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after buying an additional 2,129,449 shares during the period. AQR Capital Management LLC boosted its position in shares of Illumina by 361.7% during the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock worth $165,484,000 after buying an additional 1,662,093 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Illumina by 11,714.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company’s stock valued at $92,184,000 after purchasing an additional 1,152,048 shares during the last quarter. Brown Advisory Inc. boosted its position in Illumina by 52.1% during the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company’s stock valued at $230,818,000 after purchasing an additional 996,589 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Illumina by 51.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock valued at $155,537,000 after purchasing an additional 667,978 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on ILMN shares. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Stephens set a $110.00 price target on Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Daiwa America cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Canaccord Genuity Group increased their price target on Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research report on Friday, August 1st. Finally, Barclays increased their price target on Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research report on Thursday, October 2nd. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $115.25.

Illumina Stock Performance

ILMN opened at $100.11 on Monday. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The stock has a market cap of $15.39 billion, a price-to-earnings ratio of 12.67, a PEG ratio of 2.47 and a beta of 1.40. The business has a 50 day moving average of $98.17 and a 200-day moving average of $91.76. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the firm posted $0.36 earnings per share. The business’s revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.